

## **EXTENDED RELEASE STIMULANT AGENTS**

dexmethylphenidate extended-release (Focalin XR),
dextroamphetamine extended-release (Dexedrine Spansule)
methylphenidate controlled-delivery (Metadate CD),
methylphenidate extended-release (Metadate ER),
Adzenys XR ODT (dextroamphetamine/ amphetamine extended-release),
Aptensio XR (methylphenidate extended-release),
Cotempla XR ODT (methylphenidate extended-release)
Daytrana (methylphenidate extended-release, transdermal),
Dyanavel XR (dextroamphetamine/ amphetamine extended-release)
Methylphenidate extended-release 72 mg
Mydayis (dextroamphetamine/ amphetamine extended-release),
Quillichew ER (methylphenidate extended-release),
RELEXXII (methylphenidate extended-release)

### Diagnoses Considered for Coverage:

- Attention Deficit Hyperactivity Disorder (ADHD)
- Narcolepsy
- Binge Eating Disorder (BED) Vyvanse only

## Coverage Criteria:

#### FOR COMMERCIAL PLUS PLAN MEMBERS

- 1. For Adzenys XR ODT, Dyanavel XR, and Mydayis:
  - For diagnosis listed above, and
  - Dose does not exceed FDA label maximum, and
  - Inadequate response, intolerable side effect, or contraindication to amphetamine/ dextroamphetamine extended-release (generic Adderall XR), and
  - For patient 18 years of age or older: Being used for attention deficit hyperactivity disorder (ADHD) confirmed after 18 years old confirmed by a Mental Health Specialist (e.g. Psychiatrist, Psychologist, Behavior Therapist, Neurologist, or Nurse Practitioner mental health specialty), OR Being used for compendia or guideline supported diagnosis with psychiatric conditions- diagnosed after age 18 years old by a Mental Health Specialist (e.g. Psychiatrist, Psychologist, Behavior Therapist, Neurologist, or Nurse Practitioner mental health specialty), OR Being used for narcolepsy confirmed by a positive sleep study (polysomnography), OR Being used for binge eating disorder confirmed by a Psychiatrist, Psychologist, or Behavior Therapist Vyvanse only.

## 2. For dextroamphetamine extended-release (Dexedrine Spansule):

- For diagnosis listed above, and
- Dose does not exceed FDA label maximum, and
- Inadequate response, intolerable side effect, or contraindication to one preferred extended-release alternative including: amphetamine/ dexamphetamine (generic Adderall XR), methylphenidate extended-release (generic Ritalin LA), and methylphenidate extended-release (generic Concerta), and
- For patient 18 years of age or older: Being used for attention deficit hyperactivity disorder (ADHD) confirmed after 18 years old confirmed by a Mental Health

Specialist (e.g. Psychiatrist, Psychologist, Behavior Therapist, Neurologist, or Nurse Practitioner mental health specialty), OR Being used for compendia or guideline supported diagnosis with psychiatric conditions- diagnosed after age 18 years old by a Mental Health Specialist (e.g. Psychiatrist, Psychologist, Behavior Therapist, Neurologist, or Nurse Practitioner mental health specialty), OR Being used for narcolepsy confirmed by a positive sleep study (polysomnography), OR Being used for binge eating disorder confirmed by a Psychiatrist, Psychologist, or Behavior Therapist - Vyvanse only.

- 3. For dexmethylphenidate extended-release (Focalin XR), methylphenidate controlled-delivery (Metadate CD), methylphenidate extended-release (Metadate ER), Aptensio XR, Cotempla XR ODT, Daytrana, Quillichew ER, and Quillivant XR:
  - For diagnosis listed above, and
  - Dose does not exceed FDA label maximum, and
  - Inadequate response, intolerable side effect, or contraindication to one preferred extended-release methylphenidate alternative including: methylphenidate extended-release (generic Ritalin LA) and methylphenidate extended-release (generic Concerta), and
  - For patient 18 years of age or older: Being used for attention deficit hyperactivity disorder (ADHD) confirmed after 18 years old confirmed by a Mental Health Specialist (e.g. Psychiatrist, Psychologist, Behavior Therapist, Neurologist, or Nurse Practitioner mental health specialty), OR Being used for compendia or guideline supported diagnosis with psychiatric conditions- diagnosed after age 18 years old by a Mental Health Specialist (e.g. Psychiatrist, Psychologist, Behavior Therapist, Neurologist, or Nurse Practitioner mental health specialty), OR Being used for narcolepsy confirmed by a positive sleep study (polysomnography), OR Being used for binge eating disorder confirmed by a Psychiatrist, Psychologist, or Behavior Therapist Vyvanse only.

## **FOR COMMERCIAL STANDARD PLAN MEMBERS**

- 4. For Adzenys XR ODT, Dyanavel XR, and Mydayis:
  - For diagnosis listed above, and
  - Dose does not exceed FDA label maximum, and
  - Inadequate response, intolerable side effect, or contraindication to dextroamphetamine/ amphetamine extended-release (generic Adderall XR), and
  - For patient 18 years of age or older: Being used for attention deficit hyperactivity disorder (ADHD) confirmed after 18 years old confirmed by a Mental Health Specialist (e.g. Psychiatrist, Psychologist, Behavior Therapist, Neurologist, or Nurse Practitioner mental health specialty), OR Being used for compendia or guideline supported diagnosis with psychiatric conditions- diagnosed after age 18 years old by a Mental Health Specialist (e.g. Psychiatrist, Psychologist, Behavior Therapist, Neurologist, or Nurse Practitioner mental health specialty), OR Being used for narcolepsy confirmed by a positive sleep study (polysomnography), OR Being used for binge eating disorder confirmed by a Psychiatrist, Psychologist, or Behavior Therapist Vyvanse only.
- 5. For dextroamphetamine extended-release (Dexedrine Spansule):
  - For diagnosis listed above, and
  - Dose does not exceed FDA label maximum, and
  - Inadequate response, intolerable side effect, or contraindication to one preferred extended-release alternative including: amphetamine/ dexamphetamine (generic Adderall XR), methylphenidate extended-release (generic Ritalin LA),

methylphenidate extended-release (generic Concerta), and Vyvanse, and

• For patient 18 years of age or older: Being used for attention deficit hyperactivity disorder (ADHD) confirmed after 18 years old confirmed by a Mental Health Specialist (e.g. Psychiatrist, Psychologist, Behavior Therapist, Neurologist, or Nurse Practitioner mental health specialty), OR Being used for compendia or guideline supported diagnosis with psychiatric conditions- diagnosed after age 18 years old by a Mental Health Specialist (e.g. Psychiatrist, Psychologist, Behavior Therapist, Neurologist, or Nurse Practitioner mental health specialty), OR Being used for narcolepsy confirmed by a positive sleep study (polysomnography), OR Being used for binge eating disorder confirmed by a Psychiatrist, Psychologist, or Behavior Therapist - Vyvanse only.

# 6. For Aptensio XR, Cotempla XR ODT, Daytrana, Quillichew ER, and Quillivant XR:

- For diagnosis listed above, and
- Dose does not exceed FDA label maximum, and
- Inadequate response, intolerable side effect, or contraindication to one preferred extended-release methylphenidate alternative including: methylphenidate extended-release (generic Ritalin LA) and methylphenidate extended-release (generic Concerta), and
- For patient 18 years of age or older: Being used for attention deficit hyperactivity disorder (ADHD) confirmed after 18 years old confirmed by a Mental Health Specialist (e.g. Psychiatrist, Psychologist, Behavior Therapist, Neurologist, or Nurse Practitioner mental health specialty), OR Being used for compendia or guideline supported diagnosis with psychiatric conditions- diagnosed after age 18 years old by a Mental Health Specialist (e.g. Psychiatrist, Psychologist, Behavior Therapist, Neurologist, or Nurse Practitioner mental health specialty), OR Being used for narcolepsy confirmed by a positive sleep study (polysomnography), OR Being used for binge eating disorder confirmed by a Psychiatrist, Psychologist, or Behavior Therapist Vyvanse only.

#### FOR BRAND NAME DRUG WHEN GENERIC AVAILABLE

- 7. Dexedrine Spansule, Focalin XR, Metadate CD, or Metadate ER:
  - For diagnosis listed above, and
  - Meets coverage criteria for generic formulation, and
  - Allergic or intolerable side effect to the generic formulation.

Coverage Duration: Length of benefit

Effective: 1/01/2019GF